Volume | 114,893 |
|
|||||
News | - | ||||||
Day High | 14.64 | Low High |
|||||
Day Low | 13.87 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Alto Neuroscience Inc | ANRO | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
14.36 | 13.87 | 14.64 | 14.22 | 14.40 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
1,907 | 114,893 | $ 14.18 | $ 1,629,127 | - | 12.7798 - 24.00 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:00:00 | 2,085 | $ 14.22 | USD |
Alto Neuroscience Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
380.21M | 26.79M | - | 0 | -36.31M | -1.36 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Alto Neuroscience News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ANRO Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 13.94 | 16.535 | 13.87 | 15.41 | 73,925 | 0.28 | 2.01% |
1 Month | 13.92 | 16.535 | 12.7798 | 14.14 | 87,667 | 0.30 | 2.16% |
3 Months | 18.60 | 19.00 | 12.7798 | 14.87 | 200,115 | -4.38 | -23.55% |
6 Months | 22.00 | 24.00 | 12.7798 | 15.98 | 233,413 | -7.78 | -35.36% |
1 Year | 22.00 | 24.00 | 12.7798 | 15.98 | 233,413 | -7.78 | -35.36% |
3 Years | 22.00 | 24.00 | 12.7798 | 15.98 | 233,413 | -7.78 | -35.36% |
5 Years | 22.00 | 24.00 | 12.7798 | 15.98 | 233,413 | -7.78 | -35.36% |
Alto Neuroscience Description
Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine neuropsychiatric care by leveraging neurobiology to develop personalized and highly effective treatment options. Through our AI-enabled biomarker platform, we combine rich sources of information on patients¿ brain activity and behavior to better identify which patients are more likely to respond to our novel product candidates. |